Indian Cancer Society & AstraZeneca launch early cancer screening programme for women nationwide

Indian Cancer Society and AstraZeneca Pharma India Limited has announced the launch of a nationwide cancer awareness initiative - Cancer Screening for Women. Under this programme, free, specialized cancer-screening will be conducted across the country for women from underprivileged families. These screening camps will focus on prevalent cancers such as oral, cervical and breast and will follow a rigorous process to link the suspect cases with health care facilities for further management. The programme also aims to raise awareness about risk factors, symptoms, removing stigma, and promoting healthy lifestyle for cancer prevention. The first screening camp to mark this launch was held on World Cancer Day at Indian Cancer Society, Mumbai, where over 100 women were screened.
Mr. Naveen Kshatriya, Honorary Secretary & Managing Trustee, of the Indian Cancer Society said, “With the increasing incidence of cancer cases in women, there is an urgent need to raise awareness about early cancer detection at grass-roots level. With this initiative, we aim to enable people to stay ahead of cancer through early detection and timely treatment.’’
Commenting on the occasion, Mr. Gagan Singh, Country President and Managing Director, AstraZeneca Pharma India Limited said, “We are pleased to partner with Indian Cancer Society and other partners to achieve our shared vision of curing cancer through early detection. Women’s health is integrally linked to access to available resources and we believe that opportunistic screening with a robust framework to link them to the healthcare system is an important pathway to address this challenge”
As part of Phase 1 of this programme, around 4000 women beneficiaries from vulnerable section of society will be screened in identified high priority district areas of Maharashtra, Tamil Nadu, Kerala and Karnataka with the help of mobile detection units with qualified technicians across urban and rural areas. In Phase 2, the specialised screening camps will be expanded to states in North & North - East India. The entire programme will run over the coming years. We thank our chief Guest Shri Vishwanath Mahadeshwar The Mayor of Brihanmumbai Municipal Corporation , Mumbai and Shri Kalidas Kolambkar MLA, Wadala Constituency.
Indian Cancer Society (ICS) is India's first voluntary, non-profit, National Organization for  Awareness, Screening, Treatment Support, Survivorship and Rehabilitation, of those affected with cancer, Cancer Registry. ICS was established in 1951 by Dr. D.J. Jussawalla and Mr. Naval Tata and since then Indian Cancer Society has been doing sterling work in fighting cancer across India. ICS is actively involved with Tata Trusts, Tata Memorial Hospital, Govt of Maharashtra and various local organisations in executing awareness, screening, research and education, treatment support, survivorship and rehabilitation of cancer patient.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca India was established in 1979 and is marking its 40th year of long standing commitment to India. It is headquartered at Bengaluru, Karnataka. AstraZeneca India has a workforce of over 1200 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization.

Source:https://www.biospectrumindia.com/news/43/12725/indian-cancer-society-astrazeneca-launch-early-cancer-screening-programme-for-women-nationwide.html

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more